

# Short-chain fatty acid butyrate against TMAO activating endoplasmic-reticulum stress and PERK/IRE1-axis with reducing atrial arrhythmia

Tzu-Yu Cheng <sup>1</sup>, Ting-Wei Lee <sup>2</sup>, Shao-Jung Li <sup>3</sup>, Ting-I Lee <sup>2</sup>, Yao-Chang Chen <sup>4</sup>, Yu-Hsun Kao <sup>5</sup>, Satoshi Higa <sup>6</sup>, Pao-Huan Chen <sup>7</sup>, Yi-Jen Chen <sup>8</sup>

Affiliations expand

PMID: 39111622 DOI: [10.1016/j.jare.2024.08.009](https://doi.org/10.1016/j.jare.2024.08.009)

**Free article**

## Abstract

**Introduction:** The accumulation of microbiota-derived trimethylamine N-oxide (TMAO) in the atrium is linked to the development and progression of atrial arrhythmia. Butyrate, a major short-chain fatty acid, plays a crucial role in sustaining intestinal homeostasis and alleviating systemic inflammation, which may reduce atrial arrhythmogenesis.

**Objectives:** This study explored the roles of butyrate in regulating TMAO-mediated atrial remodeling and arrhythmia.

**Methods:** Whole-cell patch clamp experiments, Western blotting, and immunocytochemistry were used to analyze electrical activity and signaling, respectively, in TMAO-treated HL-1 atrial myocytes with or without sodium butyrate (SB) administration. Telemetry electrocardiographic recording and echocardiography and Masson's trichrome staining and immunohistochemistry were employed to

examine atrial function and histopathology, respectively, in mice treated with TMAO with and without SB administration.

**Results:** Compared with control cells, TMAO-treated HL-1 myocytes exhibited reduced action potential duration (APD), elevated sarcoplasmic reticulum (SR) calcium content, larger L-type calcium current ( $I_{Ca-L}$ ), increased  $Na^+/Ca^{2+}$  exchanger (NCX) current, and increased potassium current. However, the combination of SB and TMAO resulted in similar APD, SR calcium content,  $I_{Ca-L}$ , transient outward potassium current ( $I_{to}$ ), and ultrarapid delayed rectifier potassium current ( $I_{Kur}$ ) compared with controls. Additionally, TMAO-treated HL-1 myocytes exhibited increased activation of endoplasmic reticulum (ER) stress signaling, along with increased PKR-like ER stress kinase (PERK)/IRE1 $\alpha$  axis activation and expression of phospho-IP3R, NCX, and Kv1.5, compared with controls or HL-1 cells treated with the combination of TMAO and SB. TMAO-treated mice exhibited atrial ectopic beats, impaired atrial function, increased atrial fibrosis, and greater activation of ER stress signaling with PERK/IRE1 $\alpha$  axis activation compared with controls and mice treated with TMAO combined with SB.

**Conclusion:** TMAO administration led to PERK/IRE1 $\alpha$  axis activation, which may increase atrial remodeling and arrhythmogenesis. SB treatment mitigated TMAO-elicited ER stress. This finding suggests that SB administration is a valuable strategy for treating TMAO-induced atrial arrhythmia.

**Keywords:** Atrial remodeling; Butyrate; Endoplasmic reticulum stress; Short-chain fatty acid; Trimethylamine N-oxide.

Copyright © 2024. Production and hosting by Elsevier B.V.

[PubMed Disclaimer](#)

## Similar articles

[Galectin-3 enhances atrial remodelling and arrhythmogenesis through CD98 signalling.](#)

Cheng WL, Chen YC, Li SJ, Lee TI, Lee TW, Higa S, Chung CC, Kao YH, Chen SA, Chen YJ.

*Acta Physiol (Oxf).* 2022 Mar;234(3):e13784. doi: 10.1111/apha.13784.  
Epub 2022 Jan 17.

PMID: 34995420

## Interleukin-33/ST2 axis involvement in atrial remodeling and arrhythmogenesis.

Cheng TY, Chen YC, Li SJ, Lin FJ, Lu YY, Lee TI, Lee TW, Higa S, Kao YH, Chen YJ.

Transl Res. 2024 Jun;268:1-12. doi: 10.1016/j.trsl.2024.01.006. Epub 2024 Jan 18.

PMID: 38244770

## Macrophage migration inhibitory factor increases atrial arrhythmogenesis through CD74 signaling.

Cheng WL, Kao YH, Chen YC, Lin YK, Chen SA, Chen YJ.

Transl Res. 2020 Feb;216:43-56. doi: 10.1016/j.trsl.2019.10.002. Epub 2019 Oct 5.

PMID: 31669150

## Protein-rich foods, sea foods, and gut microbiota amplify immune responses in chronic diseases and cancers - Targeting PERK as a novel therapeutic strategy for chronic inflammatory diseases, neurodegenerative disorders, and cancer.

Saaoud F, Lu Y, Xu K, Shao Y, Praticò D, Vazquez-Padron RI, Wang H, Yang X.

Pharmacol Ther. 2024 Mar;255:108604. doi: 10.1016/j.pharmthera.2024.108604. Epub 2024 Feb 13.

PMID: 38360205      Review.

## The role of gut-dependent molecule trimethylamine N-oxide as a novel target for the treatment of chronic kidney disease.

Pan S, Zhao D, Duan S, Chen X.

Int Urol Nephrol. 2023 Jul;55(7):1747-1756. doi: 10.1007/s11255-023-03500-9. Epub 2023 Feb 16.

PMID: 36797553      Review.